Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review.


Journal

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
ISSN: 1476-4954
Titre abrégé: J Matern Fetal Neonatal Med
Pays: England
ID NLM: 101136916

Informations de publication

Date de publication:
Jun 2022
Historique:
pubmed: 9 6 2020
medline: 22 4 2022
entrez: 9 6 2020
Statut: ppublish

Résumé

COVID-19 is a pandemic disease caused by the SARS-CoV-2 and it spread globally in the last few months. The complete lack of specific treatment forced clinicians to use old drugs, chosen for their efficacy against similar viruses or their We reviewed all the available literature concerning the drugs that have been used in the treatment of COVID-19 during pregnancy and whose safe assumption during pregnancy had been demonstrated by clinical studies (i.e. including studies on other infectious diseases). Drugs contra-indicated during pregnancy or with unknown adverse effects were not included in our review. Clinical trials are not often conducted among pregnant patients for safety reasons and this means that drugs that may be effective in general population cannot be used for pregnant women due to the lack of knowledge of side effects in this category of people .The choice to use a specific drug for COVID-19 in pregnancy should take into account benefits and possible adverse events in each single case. In the current situation of uncertainty and poor knowledge about the management of COVID-19 during pregnancy, this present overview may provide useful information for physicians with practical implications.

Sections du résumé

BACKGROUND UNASSIGNED
COVID-19 is a pandemic disease caused by the SARS-CoV-2 and it spread globally in the last few months. The complete lack of specific treatment forced clinicians to use old drugs, chosen for their efficacy against similar viruses or their
METHODS UNASSIGNED
We reviewed all the available literature concerning the drugs that have been used in the treatment of COVID-19 during pregnancy and whose safe assumption during pregnancy had been demonstrated by clinical studies (i.e. including studies on other infectious diseases). Drugs contra-indicated during pregnancy or with unknown adverse effects were not included in our review.
RESULTS AND CONCLUSIONS UNASSIGNED
Clinical trials are not often conducted among pregnant patients for safety reasons and this means that drugs that may be effective in general population cannot be used for pregnant women due to the lack of knowledge of side effects in this category of people .The choice to use a specific drug for COVID-19 in pregnancy should take into account benefits and possible adverse events in each single case. In the current situation of uncertainty and poor knowledge about the management of COVID-19 during pregnancy, this present overview may provide useful information for physicians with practical implications.

Identifiants

pubmed: 32508168
doi: 10.1080/14767058.2020.1774875
pmc: PMC7284138
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2174-2187

Auteurs

Alessandro Favilli (A)

Department of Obstetrics and Gynecology, AOUI Verona, Verona, Italy.

Marta Mattei Gentili (M)

Department of Surgical and Biochemical Sciences, Centre of Perinatal and Reproductive Medicine, University of Perugia, Perugia, Italy.

Francesca Raspa (F)

Department of Surgical and Biochemical Sciences, Centre of Perinatal and Reproductive Medicine, University of Perugia, Perugia, Italy.

Irene Giardina (I)

Department of Surgical and Biochemical Sciences, Centre of Perinatal and Reproductive Medicine, University of Perugia, Perugia, Italy.

Fabio Parazzini (F)

Fondazione IRCCS Cà Granda, Dipartimento Materno-Infantile, Ospedale Maggiore Policlinico, Università degli Studi di Milano, Dipartimento di Scienze Cliniche e di Comunità, Universita' di Milano, Milan, Italy.

Amerigo Vitagliano (A)

Department of Women's and Children's Health, University of Padua, Padova, Italy.

Anna V Borisova (AV)

Department of Obstetrics and Gynecology with the Course of Perinatology, Peoples Friendship University of Russia (RUDN University), Moscow, Russian Federation.

Sandro Gerli (S)

Department of Surgical and Biochemical Sciences, Centre of Perinatal and Reproductive Medicine, University of Perugia, Perugia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH